Abemaciclib: tested on its own
45 studies: no other medicine in its arm. Page 1 of 1. Open to participants first (12), then studies with results posted, then the rest; newest registration first within each.
- Pharmacokinetic Model of Abemaciclib: Correlation With Severe Diarrhea as the Primary Toxicity Endpoint in Patients With Localized Hormone Receptor-positive Breast CancerNot yet recruitingNCT07490509Phase 4Report a problem
- Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and AbemaciclibNot yet recruitingNCT07428018Phase 2Report a problem
- Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast CancerNot yet recruitingNCT07292207Phase 2Report a problem
- A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast CancerRecruitingNCT06678269Phase 1Report a problem
- Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)RecruitingNCT06169371Phase 4Report a problem
- A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for LiposarcomasRecruitingNCT06025747Phase 1Report a problem
- Abemaciclib in Newly Diagnosed Meningioma PatientsRecruitingNCT05940493Phase 2Report a problem
- Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi SarcomaRecruitingNCT04941274Phase 1/2Report a problem
- Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical NeurofibromasRecruitingNCT04750928Phase 1/2Report a problem
- Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.RecruitingNCT04305834Phase 2Report a problem
- Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway AlterationRecruitingNCT04040205Phase 2Report a problem
- Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6RecruitingNCT03310879Phase 2Report a problem
- Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid CancerCompletedNCT04552769Phase 2Results postedReport a problem
- Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate CancerCompletedNCT04408924Phase 2Results postedReport a problem
- Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)TerminatedNCT04169074Phase 2Results postedReport a problem
- A Study to Evaluate Abemaciclib in Advanced Biliary Tract CarcinomaTerminatedNCT04003896Phase 2Results postedReport a problem
- Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast CancerTerminatedNCT03979508Phase 2Results postedReport a problem
- Abemaciclib in Patients With OligodendrogliomaCompletedNCT03969706Phase 2Results postedReport a problem
- A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast CancerCompletedNCT03703466Phase 2Results postedReport a problem
- Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast CancerTerminatedNCT03130439Phase 2Results postedReport a problem
- A Study of Abemaciclib in Recurrent GlioblastomaActive, not recruitingNCT02981940Phase 2Results postedReport a problem
- A Study of Abemaciclib (LY2835219) in Native Chinese Participants With Advanced and/or Metastatic CancersCompletedNCT02919696Phase 1Results postedReport a problem
- A Study of Abemaciclib in Healthy ParticipantsCompletedNCT02672423Phase 1Results postedReport a problem
- A Study of Abemaciclib (LY2835219) in Healthy Participants With and Without FoodCompletedNCT02482935Phase 1Results postedReport a problem
- A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung CancerCompletedNCT02450539Phase 2Results postedReport a problem
- A Study of Abemaciclib in Participants With Varying Degrees of Liver ImpairmentCompletedNCT02387814Phase 1Results postedReport a problem
- A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the BrainCompletedNCT02308020Phase 2Results postedReport a problem
- A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung CancerActive, not recruitingNCT02152631Phase 3Results postedReport a problem
- A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has SpreadCompletedNCT02102490Phase 2Results postedReport a problem
- A Study of LY2835219 in Healthy ParticipantsCompletedNCT02059148Phase 1Results postedReport a problem
- A Study of LY2835219 in Japanese Participants With Advanced CancerCompletedNCT02014129Phase 1Results postedReport a problem
- A Study of Carbon-14-Labeled LY2835219 ([^14C]-LY2835219) in Healthy ParticipantsCompletedNCT01913314Phase 1Results postedReport a problem
- Study of LY2835219 for Mantle Cell LymphomaCompletedNCT01739309Phase 2Results postedReport a problem
- SARC041: Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated LiposarcomaActive, not recruitingNCT04967521Phase 3Report a problem
- Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBCActive, not recruitingNCT04565054Phase 3Report a problem
- Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLCCompletedNCT04010357Phase 2Report a problem
- Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine TumorsActive, not recruitingNCT03891784Phase 2Report a problem
- (CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial CancerActive, not recruitingNCT03837821Early Phase 1Report a problem
- A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based TherapyStatus unknownNCT03356587Phase 2Report a problem
- Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6CompletedNCT03356223Phase 2Report a problem
- Multiorgan Metabolic Imaging Response Assessment of AbemaciclibCompletedNCT03339843Phase 2Report a problem
- Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain TumorsActive, not recruitingNCT03220646Phase 2Report a problem
- Study of Abemaciclib in Dedifferentiated LiposarcomaActive, not recruitingNCT02846987Phase 2Report a problem
- Randomized Short-term Pre-surgical Study to Assess the Effects of Abemaciclib (LY2835219) in Early Breast Cancer PatientsCompletedNCT02831530Phase 2Report a problem
- Abemaciclib in Children With DIPG or Recurrent/Refractory Solid TumorsCompletedNCT02644460Phase 1Report a problem